
Scorpion Therapeutics, Inc., a next-generation precision oncology company, has raised $162 million in Series B financing. Boxer Capital of Tavistock Group, EcoR1 Capital, LLC, Omega Funds and Vida Ventures led the round.
Source: Press Release
Scorpion Therapeutics, Inc., a next-generation precision oncology company, has raised $162 million in Series B financing.
Scorpion Therapeutics, Inc., a next-generation precision oncology company, has raised $162 million in Series B financing. Boxer Capital of Tavistock Group, EcoR1 Capital, LLC, Omega Funds and Vida Ventures led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination